Professor Xiaojie Bian: Innovative Drug Development in Prostate Cancer Is Moving Beyond ARPIs with the Emergence of Multi-Target and Multi-Platform Strategies | 2025 Pujiang Prostate Cancer Congress

Professor Xiaojie Bian: Innovative Drug Development in Prostate Cancer Is Moving Beyond ARPIs with the Emergence of Multi-Target and Multi-Platform Strategies | 2025 Pujiang Prostate Cancer Congress

2025.07.21
The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,” the event brought together leading domestic and international experts to share cutting-edge progress and clinical experience in prostate cancer. During the conference, Professor Xiaojie Bian of Fudan University Shanghai Cancer Center spoke with Oncology Frontier – Urology Frontier to discuss the current landscape and future prospects of innovative drug development for prostate cancer.
2025 BOC/BOA Kicks Off on July 4! Professor Jun Ma Invites You to Explore Global Frontiers in Hematologic Malignancies and Witness a New Era of Chinese Innovation

2025 BOC/BOA Kicks Off on July 4! Professor Jun Ma Invites You to Explore Global Frontiers in Hematologic Malignancies and Witness a New Era of Chinese Innovation

2025.07.16
The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC), held in conjunction with Best of ASCO 2025 China (BOC/BOA), will take place from July 4–5 in the historic city of Nanjing. This prestigious event will gather leading oncology experts from across China and around the world to reflect on major clinical oncology advances in China over the past year and to present key takeaways from the recently concluded American Society of Clinical Oncology (ASCO) Annual Meeting.
Wenyu Shi: Latest Advances in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis (HLH) | 2025 Hematology Translational and Innovation Conference

Wenyu Shi: Latest Advances in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis (HLH) | 2025 Hematology Translational and Innovation Conference

2025.07.16
As vibrant blossoms filled the streets of Shanghai and the Huangpu River shimmered beneath the morning sun, the 2025 Hematology Translational and Innovation Conference, held in parallel with the 10th Shanghai Lymphoid Disease Symposium, was convened from June 27 to 29. This prominent academic event brought together leading experts from China and abroad to share research achievements and foster the translation of basic science into clinical advances. With a focus on innovative therapies, professional education, and scientific communication, the conference provided a dynamic platform for collaboration and progress.